ReviewCurrent diabetes reports2019
Triglycerides: Emerging Targets in Diabetes Care? Review of Moderate Hypertriglyceridemia in Diabetes.
Review in Current diabetes reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 63 citations in OpenAlex.
- Bridging Glycemic and Lipid Control: Effects of Dapagliflozin in Co-Morbid Diabetes and Heart Failure – A Randomized Controlled TrialEndocrine, metabolic & immune disorders drug targets · 2026Trial
- The effect of an app-based dietary education on dietary intake and cardiometabolic risk markers in people with type 2 diabetes: results from a randomized controlled trial.Nutrition journal · 2025Trial
- Trial
- Legacy effect of fibrate add-on therapy in diabetic patients with dyslipidemia: a secondary analysis of the ACCORDION study.Cardiovascular diabetology · 2020Trial
- Analytical Imprecision and Reference Change Values for Longitudinal Monitoring of NCD-Related Biochemical Analytes.Diagnostics (Basel, Switzerland) · 2026Article
- Association Between Neutrophil-to-Lymphocyte Ratio and Mortality Risk Among Patients With Hyperlipidemia Across Different Glycemic Status: A Longitudinal Cohort Study From NHANES 1999-2018.Reviews in cardiovascular medicine · 2026Article
- Glucose-Lowering Properties of a Tea Formulation ContainingFood science & nutrition · 2026Article
- Ceramides may Play a Central Role in the Pathogenesis of Alzheimer's Disease: a Review of Evidence and Horizons for Discovery.Molecular neurobiology · 2025Review
- Prevalence of dyslipidemia and its association with blood pressure control in Iranian hypertensive patients: insights from STEPS 2021.Lipids in health and disease · 2025Article
- Prognostic value of triglyceride-glucose index on predicting major adverse cardiovascular events in hypertensive patients: a systematic review and meta-analysis.American journal of preventive cardiology · 2025Article
- Article
- Triglycerides as a mediator in the hyperuricemia-diabetes link: insights from a hypertensive Chinese population.Frontiers in endocrinology · 2025Article
- Remnant cholesterol is more positively related to diabetes, prediabetes, and insulin resistance than conventional lipid parameters and lipid ratios: A multicenter, large sample survey.Journal of diabetes · 2024Article
- Sex differences in circulating metabolites across glycemic status and risk of coronary heart disease.medRxiv : the preprint server for health sciences · 2024Article
- Article
- Article
- Nonlinear relationship between untraditional lipid parameters and the risk of prediabetes: a large retrospective study based on Chinese adults.Cardiovascular diabetology · 2024Article
- Association between nontraditional lipid parameters and the risk of type 2 diabetes and prediabetes in patients with nonalcoholic fatty liver disease: from the national health and nutrition examination survey 2017-2020.Frontiers in endocrinology · 2024Article
- Untargeted lipidomics analysis in women with morbid obesity and type 2 diabetes mellitus: A comprehensive study.PloS one · 2024Article
- Body composition and risk factors for cardiovascular disease in global multi-ethnic populations.International journal of obesity (2005) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
purpose of reviewModerate hypertriglyceridemia is exceedingly common in diabetes, and there is growing evidence that it contributes to residual cardiovascular risk in statin-optimized patients. Major fibrate trials yielded inconclusive results regarding the cardiovascular benefit of lowering triglycerides, although there was a signal for improvement among patients with high triglycerides and low high-density lipoprotein (HDL)-the "diabetic dyslipidemia" phenotype. Until recently, no trials have examined a priori the impact of triglyceride lowering in patients with diabetic dyslipidemia, who are likely among the highest cardiovascular-risk patients. RECENT
findingsIn the recent REDUCE IT trial, omega-3 fatty acid icosapent ethyl demonstrated efficacy in lowering cardiovascular events in patients with high triglycerides, low HDL, and statin-optimized low-density lipoprotein (LDL). The ongoing PROMINENT trial is examining the impact of pemafibrate in a similar patient population. Emerging evidence suggests that lowering triglycerides may reduce residual cardiovascular risk, especially in high-risk patients with diabetic dyslipidemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.